Latest Commercialisation News

New Murchison Gold Limited reports a significant 39% increase in indicated gold resources at its Crown Prince deposit and secures a strategic ore purchase deal with Westgold, setting the stage for mining to commence mid-2025.

Grand Gulf Energy Limited reports steady oil production and strategic progress on its helium projects, including a planned 3D seismic survey and ongoing funding discussions, while implementing cost controls in a softening market.

Starpharma reports encouraging FDA feedback on its DEP® SN38 candidate for ovarian cancer and prepares for product launches in Saudi Arabia and UAE, supported by a solid $20.3 million cash position.

Artrya Limited reports solid progress on its FDA 510(k) application and secures a A$5 million capital raise, positioning itself for imminent commercial rollout in the US healthcare sector.

Alpha HPA Limited has reached a major funding milestone with a $400 million senior debt package for its HPA First Project Stage 2, while experiencing accelerating demand from the semiconductor sector and advancing new product developments.

Neurotech International reports key clinical progress in paediatric neurological disorders, securing FDA orphan drug designation for its Rett Syndrome treatment and advancing pivotal trials for ASD and PANDAS/PANS.

Bio-Gene Technology Limited has been awarded two U.S. Department of Defense grants totaling A$3 million to develop innovative insect control products targeting military and civilian markets.

Algorae Pharmaceuticals reports robust progress in its drug development pipeline, highlighted by promising preclinical results for cardiovascular and dementia candidates and significant AI platform enhancements.

Livium Ltd reports a 179% surge in recycling gross profit and advances its lithium extraction technology, positioning itself strongly in the evolving battery materials market.

MTM Critical Metals reports solid progress on its US-based Flash Joule Heating demonstration plant, targeting a Q4 2025 start-up in Texas amid favorable regulatory and funding prospects.

Hiremii Limited reports a modest 0.4% revenue increase to $7.5 million in Q2 FY25, underpinned by strategic AI platform deployment and expanding Energy Transition sector opportunities.

Noxopharm’s December 2024 quarterly report reveals expanding global interest in its Sofra technology through new Material Transfer Agreements and a strengthened cash position following a significant R&D tax rebate.